This modest difference in awareness may reflect the more intuitive understanding of SGLT2-inhibitors as glucose-lowering agents in T2DM—due to their mechanism of promoting urinary glucose excretion—versus the more complex and less familiar cardiorenal benefits in heart failure management.19 Here, SLC5A2 is linked to type 2 diabetes mellitus.